JP5641677B2 - ヒトの分娩を容易にするための新規組成物 - Google Patents
ヒトの分娩を容易にするための新規組成物 Download PDFInfo
- Publication number
- JP5641677B2 JP5641677B2 JP2007540579A JP2007540579A JP5641677B2 JP 5641677 B2 JP5641677 B2 JP 5641677B2 JP 2007540579 A JP2007540579 A JP 2007540579A JP 2007540579 A JP2007540579 A JP 2007540579A JP 5641677 B2 JP5641677 B2 JP 5641677B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- present
- composition according
- propylene glycol
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 99
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 38
- 229920002125 Sokalan® Polymers 0.000 claims description 30
- 239000000314 lubricant Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 18
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 18
- 239000004584 polyacrylic acid Substances 0.000 claims description 13
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- 208000034423 Delivery Diseases 0.000 claims description 10
- 230000009677 vaginal delivery Effects 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001691 amnion Anatomy 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 12
- 230000001050 lubricating effect Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 9
- 210000002826 placenta Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- -1 silver ions Chemical class 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- 210000004381 amniotic fluid Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000032696 parturition Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229920000148 Polycarbophil calcium Polymers 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229950005134 polycarbophil Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 230000009352 congenital transmission Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960002358 iodine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046820 Uterine rupture Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 description 1
- 229960002403 atosiban Drugs 0.000 description 1
- 108700007535 atosiban Proteins 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010015964 lucinactant Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 description 1
- 229960003400 sulprostone Drugs 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(i)ポリアクリル酸(a)と水(d)とからなる第一の混合物を、場合により毒性をたとえばNaClの添加により、および/またはpH値を塩基、たとえばNaOHの添加により調整しながら製造する工程、その際、第一の混合物は有利にはゲルとして存在している、
(ii)水溶性の増粘剤(b)、保湿剤(c)および水(d)からなる第二の混合物を製造する工程、その際、第二の混合物は有利にはゲルとして存在している、
(iii)両方の混合物を合する工程、
(iv)場合により均質化する工程および
(v)場合により滅菌する工程。
実施例
A 調製物の例
調製物例1
塩化ナトリウム:4.95mg/g、
プロピレングリコール:200.00mg/g、
Carbopol(登録商標)940:4.85mg/g、
ヒドロキシエチルセルロース(Natrosol 250G):45.00mg/g、
精製水:745.20mg/g。
塩化ナトリウム:4.95mg/g、
水酸化ナトリウム(5N):2.00mg/g、
プロピレングリコール:200.00mg/g、
Carbopol(登録商標)980NF:4.85mg/g、
ヒドロキシエチルセルロース(Natrosol 250G):45.00mg/g、
精製水:743.20mg/g。
塩化ナトリウム:0.495%(m/m)、
プロピレングリコール:20.0%(m/m)、
ヒドロキシエチルセルロース(Natrosol 250M):2.5%(m/m)、
Carbopol980NF:0.485%(m/m)、
水酸化ナトリウム(5N):0.85%(m/m)、
精製水:75.67%(m/m)。
塩化ナトリウム:4.95mg/g、
プロピレングリコール:200.00mg/g、
Noveon AA−1USP Polycarbophil:4.85mg/g、
ヒドロキシエチルセルロース(Natrosol 250G):45.00mg/g、
精製水:745.20mg/g。
塩化ナトリウム:4.95mg/g、
水酸化ナトリウム(5N):2.00mg/g、
プロピレングリコール:200.00mg/g、
Noveon AA−1USP Polycarbophil:4.85mg/g、
ヒドロキシエチルセルロース(Natrosol 250G):45.00mg/g、
精製水:743.20mg/g。
塩化ナトリウム:0.495%(m/m)、
プロピレングリコール:20.0%(m/m)、
ヒドロキシエチルセルロース(Natrosol 250M):2.5%(m/m)、
Naveon AA−1USP Polycarbophil:4.85mg/g、
水酸化ナトリウム(5N):0.85%(m/m)、
精製水:75.67%(m/m)。
pH値:5.5〜6.0、
粘度:約10〜18Pa・s(回転粘度計)(Pa・s=Paxs)、
比重:1.032〜1.042g/cm3、
導電性:8.0〜12.0mS・cm-1、
屈折率nD 20:1.361(1.26〜1.46)、
水結合能:高、
粘液接着性:高。
δ20℃=m・0.99703+0.0012(g/cm3)δ
により行う。
W=同一の体積の水の質量、空気中で秤量。
1000個の注射器にそれぞれ10gずつ包装するための10kgの製造
最初にホモジナイザー(Tornado ET21)中で塩化ナトリウム49.5gを水500g中に完全に溶解した。次いでポリアクリル酸(Carbopolum(登録商標)940)48.5gおよび水2000gを添加し、かつ撹拌下で5分間混合した。次いで撹拌下に10分間、pH値が5.5〜5.6に調整されるまで、10%のNaOH水溶液を添加した。こうして製造したゲル(混合物1)を、室温で加工するまで貯蔵した。
例1:
ヒトにおける出産の際の開口期および娩出期を容易にするために潤滑剤の使用
8人の初産婦の集団において、本発明の潤滑ゲルを適用した。このために、通常どおりに潤滑ゲルを膣の試験のために使用するのみでなく、産道を間欠的に手作業で潤滑剤により覆った。このために必要とされる潤滑ゲルの量は、膣の試験のために使用する場合の10〜15倍であった。この試験集団において、平均的な分娩時間が、確立された標準値に対して顕著に短くなり、かつ女性は、潤滑剤を適用しなかった比較可能な初産婦よりも総じて容易に経膣分娩したことを確認することができた。総じて母と子の分娩トラウマはより少なかった。さらに、この試験集団において、膣の手術による分娩終了を実施する必要がなく、かつ産道の損傷、たとえば膣の亀裂は確認されなかった。
胎盤のはく離を容易にするための潤滑剤の使用
産後に胎盤を保持している5人の患者の集団において、手作業による胎盤の剥離を容易にするために、潤滑剤を助産師の腕と産道に適用した。その際、手作業による胎盤の剥離がより容易に、かつ迅速に行うことができ、かつこのことによって血液の損失を低減することができた。
試験の実施
以下に記載する文献箇所に基づいて、本発明による調製物例2に関して生体適合性試験を実施した:
1."In Vitro Fertilization and Embryo Transfer" A Manual of Basic Techniques. Wolf, Don P.編、New York & London: Plenum Press、第5:Mouse Embryo Culture Bioassay、第57〜76頁、1988年。
2.ISO10993−12、2002、Biological Evaluation of Medical Devices - Part 12: Sample Preparation and Reference Materials。
3.ISO/IEC 17025、2005年、General Requirements for the Competence of Testing and Calibration Laboratories。
72時間の曝露後、本発明による調製物2の抽出物に関して、陰性対照と比較して生存能力のあるマウス胚の数の顕著な低下は観察されなかったが、他方、陽性対照は、生存能力のあるマウス胚の数の明らかな低下を生じた。この試験結果を考慮して、本発明による調製物例2は、胚に対して毒性ではないと評価された。
Claims (16)
- (a)架橋したポリアクリル酸、その際、架橋したポリアクリル酸は、組成物の全質量に対して0.4〜0.7%の質量割合で存在しており、
(b)水溶性増粘剤としてヒドロキシエチルセルロース、その際、ヒドロキシエチルセルロースは、組成物の全質量に対して1〜10%の質量割合で存在しており、および
(c)保湿剤としてプロピレングリコール、その際、プロピレングリコールは、組成物の全質量に対して15〜25%の質量割合で存在しており、および
(d)水
を含有する、ヒトの経膣分娩用潤滑剤組成物。 - 4〜7の範囲のpH値を有することを特徴とする、請求項1記載の組成物。
- 5.5〜6の範囲のpH値を有することを特徴とする、請求項1または2記載の組成物。
- 1〜40Pa・sの粘度を有することを特徴とする、請求項1から3までのいずれか1項記載の組成物。
- 10〜18Pa・sの粘度を有することを特徴とする、請求項1から4までのいずれか1項記載の組成物。
- チキソトロープおよび/または構造粘性の特性を有することを特徴とする、請求項1から5までのいずれか1項記載の組成物。
- 4〜25mS・cm-1の導電性を有することを特徴とする、請求項1から6までのいずれか1項記載の組成物。
- 8〜12mS・cm-1の導電性を有することを特徴とする、請求項1から7までのいずれか1項記載の組成物。
- ほぼ等容量オスモル濃度を有することを特徴とする、請求項1から8までのいずれか1項記載の組成物。
- 滅菌されていることを特徴とする、請求項1から9までのいずれか1項記載の組成物。
- 保存剤を含有していないことを特徴とする、請求項1から10までのいずれか1項記載の組成物。
- ゲルの形で、固体の投与形として、懸濁剤として、またはフォームとして存在していることを特徴とする、請求項1から11までのいずれか1項記載の組成物。
- さらに少なくとも1種の医薬作用物質を含有していることを特徴とする、請求項1から12までのいずれか1項記載の組成物。
- 規則的な陣痛の開始前および/または開始後に、1回または複数回適用することを特徴とする、請求項1から13までのいずれか1項記載の組成物。
- 産道中に、場合により子宮口および/または羊膜内を含めて適用することを特徴とする、請求項1から14までのいずれか1項記載の組成物。
- (a)架橋したポリアクリル酸、その際、架橋したポリアクリル酸は、組成物の全質量に対して0.4〜0.7%の質量割合で存在しており、
(b)水溶性増粘剤としてヒドロキシエチルセルロース、その際、ヒドロキシエチルセルロースは、組成物の全質量に対して1〜10%の質量割合で存在しており、および
(c)保湿剤としてプロピレングリコール、その際、プロピレングリコールは、組成物の全質量に対して15〜25%の質量割合で存在しており、および
(d)水
を含有する、胎盤剥離用潤滑剤組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004054552.9 | 2004-11-11 | ||
DE102004054552A DE102004054552A1 (de) | 2004-11-11 | 2004-11-11 | Neue Zusammensetzung zur Erleichterung der Humangeburt |
PCT/EP2005/012058 WO2006050951A1 (de) | 2004-11-11 | 2005-11-10 | Neue zusammensetzung zur erleichterung der humangeburt |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013035709A Division JP2013100364A (ja) | 2004-11-11 | 2013-02-26 | ヒトの分娩を容易にするための新規組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008519791A JP2008519791A (ja) | 2008-06-12 |
JP5641677B2 true JP5641677B2 (ja) | 2014-12-17 |
Family
ID=35613872
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007540579A Expired - Fee Related JP5641677B2 (ja) | 2004-11-11 | 2005-11-10 | ヒトの分娩を容易にするための新規組成物 |
JP2013035709A Pending JP2013100364A (ja) | 2004-11-11 | 2013-02-26 | ヒトの分娩を容易にするための新規組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013035709A Pending JP2013100364A (ja) | 2004-11-11 | 2013-02-26 | ヒトの分娩を容易にするための新規組成物 |
Country Status (18)
Country | Link |
---|---|
US (2) | US8703171B2 (ja) |
EP (1) | EP1809239A1 (ja) |
JP (2) | JP5641677B2 (ja) |
KR (1) | KR20070090181A (ja) |
CN (1) | CN101087587A (ja) |
AR (1) | AR052030A1 (ja) |
AU (1) | AU2005303970B2 (ja) |
BR (1) | BRPI0517799A (ja) |
CA (1) | CA2585976C (ja) |
DE (1) | DE102004054552A1 (ja) |
EA (1) | EA012391B1 (ja) |
IL (1) | IL182977A (ja) |
MX (1) | MX2007005587A (ja) |
MY (1) | MY144274A (ja) |
TW (1) | TW200631603A (ja) |
UA (1) | UA91526C2 (ja) |
WO (1) | WO2006050951A1 (ja) |
ZA (1) | ZA200703777B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005030011A1 (de) | 2005-06-17 | 2006-12-21 | Aesculap Ag & Co. Kg | Verfahren zur Herstellung von sterilen Polysaccharidlösungen |
EP1886676A1 (en) * | 2006-08-09 | 2008-02-13 | Polichem S.A. | Compositions with enhanced elasticizing activity |
GB2456212B (en) * | 2008-01-09 | 2012-04-25 | Lrc Products | Lubricant mousse |
US20090185995A1 (en) * | 2008-01-18 | 2009-07-23 | Stacy Vochecowicz | Lubricious, non-tacky personal lubricant |
MD335Z (ro) * | 2010-11-19 | 2011-10-31 | Родика КАТРИНИЧ | Metodă de pregătire a colului uterin pentru inducerea travaliului la gestantele cu sarcină prolongată |
CN102228720A (zh) * | 2011-06-27 | 2011-11-02 | 江苏康宝医疗器械有限公司 | 产妇分娩安全生理润滑剂及其制备方法 |
CN102512338A (zh) * | 2012-01-13 | 2012-06-27 | 北京国联诚辉医药技术有限公司 | 一种水溶性人体润滑剂及其制备方法 |
CN103100115B (zh) * | 2012-04-28 | 2014-07-09 | 尹颖 | 一种产道润滑组合物 |
KR20150038174A (ko) * | 2012-07-26 | 2015-04-08 | 훼링 비.브이. | 미소프로스톨 조성물 |
US9166536B2 (en) | 2012-10-30 | 2015-10-20 | Eta Devices, Inc. | Transmitter architecture and related methods |
WO2014152154A1 (en) * | 2013-03-14 | 2014-09-25 | Church & Dwight Co., Inc. | Aqueous lubricant composition |
CN103340824A (zh) * | 2013-07-09 | 2013-10-09 | 宁波华欣医疗器械有限公司 | 一种助产凝胶剂及其制备方法 |
CN103536969B (zh) * | 2013-09-29 | 2014-09-24 | 辽宁亿灵科创生物医药科技有限公司 | 具有一定粘度预防分娩损伤的润滑组合物 |
CN107412885B (zh) * | 2014-01-13 | 2020-04-28 | 成都英诺新科技有限公司 | 一种助产用凝胶及其制备方法 |
EP3169324B1 (en) * | 2014-07-14 | 2019-05-08 | Orion Biotechnology Canada Ltd. | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof |
WO2017180174A1 (en) | 2016-04-15 | 2017-10-19 | Fairhaven Health, Llc | Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract |
US20180369137A1 (en) * | 2017-06-27 | 2018-12-27 | Lifestyles Healthcare Pte. Ltd. | Natural Lubricant |
WO2019059856A1 (en) * | 2017-09-22 | 2019-03-28 | Turkuaz Sağlik Hi̇zmetleri̇ Medi̇kal Temi̇zli̇k Ki̇myasal Ürünler Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | OBSTETRIC GEL AND METHOD OF PRODUCTION |
CN110269958B (zh) * | 2018-03-17 | 2021-11-23 | 北京旭泽医药科技有限公司 | 一种含有卡波姆的助产凝胶组合物及其制备方法 |
RU2723596C1 (ru) * | 2019-09-12 | 2020-06-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ прогнозирования риска развития слабости родовой деятельности у женщин разных соматотипов |
CN111066964A (zh) * | 2019-12-26 | 2020-04-28 | 湖北回盛生物科技有限公司 | 反刍动物用液体润滑剂及其制备方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5442909B1 (ja) | 1970-12-21 | 1979-12-17 | ||
US3971848A (en) | 1970-12-21 | 1976-07-27 | Kimitsu Chemical Laboratory Co. Ltd. | Lubricating composition for mucosa or epidermis |
JPS4948725B1 (ja) | 1971-06-24 | 1974-12-23 | ||
US4184974A (en) * | 1974-05-16 | 1980-01-22 | Leuven James W Van | Liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
US4267168A (en) * | 1977-03-11 | 1981-05-12 | Aquatain Partnership | Method of reducing bacteria on human tissue using liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
GB8323624D0 (en) | 1983-09-02 | 1983-10-05 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
AU565354B2 (en) | 1983-11-14 | 1987-09-10 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
JPS61195196A (ja) * | 1985-02-25 | 1986-08-29 | Nippon Steel Chem Co Ltd | 高温用潤滑剤組成物 |
CA1257545A (en) * | 1985-05-23 | 1989-07-18 | Hans A. Schaeffer | Dental composition, method of preparation thereof and container therefor |
GB8622698D0 (en) | 1986-09-20 | 1986-10-29 | Smith & Nephew Ass | Dispenser |
US4859242A (en) * | 1987-03-16 | 1989-08-22 | Color Quest Inc. | Water soluble coloring compositions containing sparkle components |
US4981686A (en) | 1987-05-18 | 1991-01-01 | Hardy Robert E | Personal lubricant |
GB8817015D0 (en) | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
WO1992009256A1 (en) | 1990-12-03 | 1992-06-11 | Medical Polymers, Inc. | Water-based human tissue lubricant |
US5342617A (en) | 1990-12-03 | 1994-08-30 | Medical Polymers, Inc. | Water-based human tissue lubricant |
JP3042546B2 (ja) * | 1991-04-23 | 2000-05-15 | 昭和電工株式会社 | 微粒子状の架橋型n−ビニルアミド樹脂及びミクロゲル、その製造法及び用途 |
YU66892A (sh) | 1991-08-20 | 1995-10-24 | Hoechst Ag. | Fosfoinositolglikan - peptid sa delovanjem kao insulin |
IL100881A (en) | 1992-02-06 | 1996-06-18 | Porat Michael | Causal drug prevents diseases, devices and methods of using it |
NL9400160A (nl) | 1994-02-02 | 1995-09-01 | Stichting Tech Wetenschapp | Therapeutische samenstelling voor het vervangen en/of aanvullen van lichaamsvloeistoffen. |
US5580574A (en) | 1994-04-28 | 1996-12-03 | Hoffmann-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
US5599534A (en) | 1994-08-09 | 1997-02-04 | University Of Nebraska | Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use |
US20020061864A1 (en) | 1994-09-22 | 2002-05-23 | Geda International Marketing Company Ltd. | Antiseptic spermicidal composition and means for its application |
ATE239068T1 (de) | 1995-06-07 | 2003-05-15 | Lee County Mosquito Control Di | Schmiermittelzusammensetzungen und verfahren |
DE19531893A1 (de) | 1995-08-30 | 1997-03-06 | Bayer Ag | Juckreizmildernde, kosmetische und/oder pharmazeutische Zusammensetzungen |
US6596777B1 (en) | 1997-05-29 | 2003-07-22 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes |
US5885591A (en) | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
IT1284874B1 (it) | 1996-08-02 | 1998-05-22 | Farmigea Spa | Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici |
US5877209A (en) | 1996-11-07 | 1999-03-02 | Yunis; Adel A. | Hair follicle protective formulations |
US6462028B2 (en) | 1997-07-25 | 2002-10-08 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
EP1109563A4 (en) * | 1998-08-04 | 2009-07-22 | Madash Llp | HEAT-SENSITIVE HYDROGELS WITH MODIFIED TERMINATION |
US6139848A (en) | 1999-02-12 | 2000-10-31 | Mcneil-Ppc, Inc. | Personal lubricant compositions |
JP2002029993A (ja) * | 1999-08-05 | 2002-01-29 | Taisho Pharmaceut Co Ltd | 貼付剤 |
RU2177789C2 (ru) | 1999-11-19 | 2002-01-10 | Общество с ограниченной ответственностью Научно-производственное предприятие "Тульская индустрия LTD" | Средство, способствующее созреванию шейки матки, способ ускорения созревания шейки матки и устройство для доставки лекарственного средства к шейке матки |
GB0007842D0 (en) | 2000-03-31 | 2000-05-17 | Spruce Barbara | Sigma receptor ligands and their medical uses |
US20030114394A1 (en) | 2001-10-29 | 2003-06-19 | Levine Howard L. | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US7709026B2 (en) | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
CH697081A5 (de) * | 2002-01-22 | 2008-04-30 | Andreas F Dr Schaub | Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten. |
AU2003275069A1 (en) * | 2002-09-20 | 2004-04-08 | La Jolla Biosciences | Compositions and methods for preventing infection |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
JP4624256B2 (ja) | 2005-12-28 | 2011-02-02 | 三洋電機株式会社 | 透光体を選択的に配置する電気機器 |
-
2004
- 2004-11-11 DE DE102004054552A patent/DE102004054552A1/de not_active Ceased
-
2005
- 2005-11-09 TW TW094139313A patent/TW200631603A/zh unknown
- 2005-11-09 AR ARP050104695A patent/AR052030A1/es not_active Application Discontinuation
- 2005-11-10 MX MX2007005587A patent/MX2007005587A/es active IP Right Grant
- 2005-11-10 US US11/718,995 patent/US8703171B2/en not_active Expired - Fee Related
- 2005-11-10 EA EA200701029A patent/EA012391B1/ru not_active IP Right Cessation
- 2005-11-10 UA UAA200706411A patent/UA91526C2/uk unknown
- 2005-11-10 JP JP2007540579A patent/JP5641677B2/ja not_active Expired - Fee Related
- 2005-11-10 MY MYPI20055275A patent/MY144274A/en unknown
- 2005-11-10 CN CNA2005800444923A patent/CN101087587A/zh active Pending
- 2005-11-10 AU AU2005303970A patent/AU2005303970B2/en not_active Ceased
- 2005-11-10 WO PCT/EP2005/012058 patent/WO2006050951A1/de active Application Filing
- 2005-11-10 CA CA2585976A patent/CA2585976C/en not_active Expired - Fee Related
- 2005-11-10 EP EP05802296A patent/EP1809239A1/de not_active Withdrawn
- 2005-11-10 KR KR1020077012725A patent/KR20070090181A/ko not_active Application Discontinuation
- 2005-11-10 BR BRPI0517799-5A patent/BRPI0517799A/pt not_active IP Right Cessation
-
2007
- 2007-05-03 IL IL182977A patent/IL182977A/en active IP Right Grant
- 2007-05-10 ZA ZA200703777A patent/ZA200703777B/en unknown
-
2013
- 2013-02-26 JP JP2013035709A patent/JP2013100364A/ja active Pending
-
2014
- 2014-03-04 US US14/196,157 patent/US20140187650A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2585976C (en) | 2014-04-29 |
BRPI0517799A (pt) | 2008-10-21 |
KR20070090181A (ko) | 2007-09-05 |
US20140187650A1 (en) | 2014-07-03 |
JP2008519791A (ja) | 2008-06-12 |
US8703171B2 (en) | 2014-04-22 |
MY144274A (en) | 2011-08-29 |
JP2013100364A (ja) | 2013-05-23 |
TW200631603A (en) | 2006-09-16 |
WO2006050951A1 (de) | 2006-05-18 |
UA91526C2 (uk) | 2010-08-10 |
EP1809239A1 (de) | 2007-07-25 |
CA2585976A1 (en) | 2006-05-18 |
IL182977A0 (en) | 2007-08-19 |
MX2007005587A (es) | 2007-07-11 |
EA200701029A1 (ru) | 2007-10-26 |
DE102004054552A1 (de) | 2006-05-18 |
EA012391B1 (ru) | 2009-10-30 |
ZA200703777B (en) | 2008-07-30 |
AU2005303970B2 (en) | 2010-08-05 |
CN101087587A (zh) | 2007-12-12 |
IL182977A (en) | 2016-08-31 |
AU2005303970A1 (en) | 2006-05-18 |
AR052030A1 (es) | 2007-02-28 |
US20080103214A1 (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5641677B2 (ja) | ヒトの分娩を容易にするための新規組成物 | |
Valenta | The use of mucoadhesive polymers in vaginal delivery | |
BRPI0109078B1 (pt) | composição antimicrobiana e contraceptiva que reduz o risco de transmissão ou infecção por doença sexualmente transmitida através de atividade sexual | |
ES2550815T3 (es) | Composiciones antimicrobianas acuosas que contienen carragenanos | |
HUT77527A (hu) | Szexuális úton átvihető betegségek elleni készítmény és alkalmazása | |
BR112018009010B1 (pt) | Uso de um compósito polimérico de sol-gel para prevenir ou tratar mastite em um mamífero não humano fêmea que tem um período de lactação e sistema para formar uma barreira física no canal ou cisterna da teta do dito mamífero | |
AU2001243431A1 (en) | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | |
CN102784416B (zh) | 一种助分娩凝胶 | |
RU2697051C2 (ru) | Комбинированный лекарственный препарат для профилактики инфекций, передающихся половым путём | |
Exalto et al. | Safety aspects and side-effects of ExEm-gel and foam for uterine cavity distension and tubal patency testing | |
JP2024529479A (ja) | 膣挿入のための組成物及び技術 | |
JP6149109B2 (ja) | 乳酸オリゴマー含有医薬組成物 | |
KR20160103036A (ko) | 알긴산계 항균성 화합물을 사용하는 염증 및 질병을 억제하기 위한 조성물 및 방법 | |
KR20150018636A (ko) | 피임 살균제의 효능을 증강시키기 위한 조성물 및 방법 | |
JP4846198B2 (ja) | ヒトの出産を容易にするための組成物 | |
Veiga et al. | Polymer gels in vaginal drug delivery systems | |
CN102772426A (zh) | 壳聚糖作为助分娩润滑剂成分的医药用途 | |
CN110269958B (zh) | 一种含有卡波姆的助产凝胶组合物及其制备方法 | |
CN103536969B (zh) | 具有一定粘度预防分娩损伤的润滑组合物 | |
ITMI20002117A1 (it) | Uso di sodio nitroprussiato in ostetricia e ginecologia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080908 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101227 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130226 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130322 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130412 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140428 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140527 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140627 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5641677 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |